We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
Date | Subject | Author | Discuss |
---|---|---|---|
25/8/2016 10:46 | I pondered and added at 1630 | badtime | |
25/8/2016 10:28 | Dividend will be rebased next Spring, pretty sure on that, You have two more payments at the current level from memory. Any dividend cut will be share price supportive as it will be sold as an investment for growth. If you read between the lines of the Chairman's statement in the last Annual report this is very clear imv. | essentialinvestor | |
25/8/2016 10:15 | anhar Just looking for a good entry point as the share price has went up a lot in the last few weeks......but agree with what you say in buying for the dividend and as long as the fundamentals don't change. | spcecks | |
25/8/2016 09:41 | Clinton joined senators Susan Collins and Claire McCaskill in highlighting US-based Mylan's 480% hike in the price of its EpiPen epinephrine product since the company acquired it in 2007.Sending signals about the potential direction of drug policy if she wins the presidential race, Clinton called on Mylan to drop the price of EpiPen, which has leapt from $100 for a two-pack in 2007 to around $600 today."That's outrageous - and it's just the latest troubling example of a company taking advantage of its consumers," Clinton said in a statement."It's wrong when drug companies put profits ahead of patients, raising prices without justifying the value behind them."Senators Collins and McCaskill have called for an "urgent briefing" with Mylan's chief executive officer Heather Bresch following a public clamour for a government reaction to the pharma industry's freewheeling price increases.The senators noted that Mylan's "profitability appears to have skyrocketed" during the period, raising concerns that the price increases "were not driven by increased costs of production or product improvements".Mylan said in a statement that ensuring access to epinephrine is "a core part of our mission" and highlighted that 80% of commercially insured patients on their assistance program received the product at no cost in 2015.Not long before 0930 on Thursday, Hikma was down 4.71% to 2,123p, Shire was 4.1% lower at 4,819p, AstraZeneca by 2.5% to 4,954p and GlaxoSmithKline sliding 1.6% to 1,632.5p. | mj19 | |
25/8/2016 09:35 | And rightly so Dr from what I have read. Buying in to buoyant sentiment in the stock market is usually a quick way to the poorhouse, give me some caution any day. | essentialinvestor | |
25/8/2016 09:27 | Looking to buy in for the dividend....would appreciate any chartists view with any thoughts on a good entry price I find that odd. Charting is nonsense in my view, but even forgetting that, why would a dividend player consider charts which are about predicting price action and have nothing to do with dividend or yield? I'm an income investor, that's the only reason I invest in shares at all and specifically high yielders. To me, it follows that if using shares for income the timing device of when to get in and out ought to be directly related to the reason you want to invest. That means logically some dividend/yield related method. So if the yield is high, then it's buying time and vice versa. There are various ways you could do it, I use the yield relative to the FTSE100. GSK which I've held for years still yields well above that so is a buy at any price in my approach, assuming the underlying fundamentals remain attractive, until its yield is no longer much above the then index. If I was looking to buy it now, what would price action or charts matter? | anhar | |
25/8/2016 09:22 | Clinton going after mylan last night won't help sentiment. | dr biotech | |
25/8/2016 08:27 | Added a few on the dip. | essentialinvestor | |
24/8/2016 19:02 | warranty Also agree with what you say a good entry point and being a long term holder and just collect the dividends.....Thanks also for your advice. | spcecks | |
24/8/2016 18:56 | The bubble looks in bonds ATM, not equities. Equities can correct at any point and by most historical measures we are late in this bull market. Expected a minor give back of 3-4% in August which has not happened. Overall trend looks higher for Autumn, just a best guess. | essentialinvestor | |
24/8/2016 18:55 | bracke Agree with your post on savers driving certain share prices higher so looking for a good entry point.....Thanks again good sound advice. | spcecks | |
24/8/2016 18:26 | Spot on bracke and it will probably happen before too long. That's when having a good entry point and holding for the dividend is at it's most valuable. If you're comfortable just collecting that dividend then the day to day share price movements are largely irrelevant. As you say, it's never nice to see your SP's drop but if you're a long termer you'd know it's all part of the rich tapestry of investing. | warranty | |
24/8/2016 13:40 | spcecks Yes the low interest rates are driving savers into shares and other assets which obviously drives up the prices. The problem comes when the buying pressure slows or ceases and prices start to drop. That's when it can be unpleasant especially for those who have little knowledge of the market. | bracke | |
24/8/2016 13:31 | Thanks bracke much appreciated will wait to see what happens on Friday....So fed up with the low interest rates on saving accounts ......have decided to buy some quality dividend stocks any ideas appreciated. | spcecks | |
24/8/2016 12:35 | The probability is that the share price will test support at 1625 (magenta line). This may be influenced by what occurs at Jackson Hole on Friday. | bracke | |
24/8/2016 12:14 | Looking to buy in for the dividend....would appreciate any chartists view with any thoughts on a good entry price. | spcecks | |
24/8/2016 11:55 | Quite relieved that I took my money off the table at 1700. | salpara111 | |
24/8/2016 09:27 | SOLD: 12,341 shares @1655p .... ;0) | tradermichael | |
17/8/2016 17:44 | Dividends are not an illusion but in some cases perhaps their sustainability is. Dividends at the expense of pension contributions is another thing to be aware of. | greenpastures2 | |
17/8/2016 11:57 | Agreed with investment "illusions". That's one reason I focus on divs. They are not an illusion but an actual cash payment. The share price and its wandering random movement is an illusion, at least until one of my rare sells then it becomes the reality of cash. But is quickly turned back into an illusion when I reinvest it into a new HY share. Charts, hundreds of different opinions on bulletin boards, those are illusions where you see what you want to see, hear what you want to hear, wholly subjective reactions influenced by classic small investor psych. weaknesses like confirmation bias and recent events bias. | anhar | |
17/8/2016 11:28 | Indeed - in fact you could argue that "MUCH" is a £1.57 trillion illusion! | fangorn2 | |
17/8/2016 08:59 | That is the danger with many of the commentaries and many of the posts around the place - much is an illusion. | alphorn | |
17/8/2016 07:47 | ADRs were $43 in May and are now about $44...in USD terms the price hasn't changed | dr biotech |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions